Articles →

Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma

Access Free

Patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors or antiangiogenic tyrosine kinase inhibitors may develop resistance driven by gut dysbiosis, which disrupts the MAdCAM-1–α4β7 axis and promotes the recruitment of immunosuppressive IL-17-producing T regulatory (Tr17) cells into tumors.

Notably, low sMAdCAM-1 levels were associated with an immunosuppressive gut microbiota profile dominated by Enterocloster species. Therefore, sMAdCAM-1 deserves further investigations as a biomarker-guided tool for microbiota-targeted interventions.

More articles